Quick Answer
Regen BioPharma Inc reported Stockholders Equity of -$6.28 million for the year ending 2025.
- Regen BioPharma Inc showed a decrease of -20.4% in Stockholders Equity from 2024 to 2025.
- This data is from Regen BioPharma Inc's annual report (Form 10-K), filed with the SEC on December 30, 2025.
- XBRL data for this metric is available from 2017 to 2025 (27 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2018: -$9.12 million | Q4 2018: -$8.66 million | Q1 2019: -$8.82 million | Q2 2019: -$12.79 million | Q3 2019: -$10.91 million | Q4 2019: -$7.70 million | Q1 2020: -$11.77 million | Q2 2020: -$8.56 million | Q4 2020: -$5.58 million | Q1 2021: -$5.07 million | Q4 2022: -$4.88 million | Q1 2023: -$4.93 million | Q2 2023: -$5.03 million | Q4 2023: -$5.24 million | Q1 2024: -$5.18 million | Q2 2024: -$5.16 million | Q3 2024: -$5.22 million | Q4 2024: -$5.68 million | Q1 2025: -$5.70 million | Q2 2025: -$5.82 million | Q3 2025: -$6.28 million | Q4 2025: -$6.57 million.
- Over the full 27 years of available data (2017 to 2025), Regen BioPharma Inc's Stockholders Equity has declined by 358.1%.
- Historical annual values: Fiscal year 2025: -$6.28 million | Fiscal year 2024: -$5.22 million | Fiscal year 2023: -$5.10 million | Fiscal year 2023: -$5.03 million | Fiscal year 2023: -$4.93 million | Fiscal year 2022: -$4.88 million | Fiscal year 2022: -$8.04 million | Fiscal year 2022: -$8.35 million | Fiscal year 2022: -$76.75 million | Fiscal year 2021: -$9.76 million | Fiscal year 2021: -$13.49 million | Fiscal year 2021: -$12.41 million | Fiscal year 2020: -$7.33 million | Fiscal year 2020: -$8.56 million | Fiscal year 2020: -$11.77 million | Fiscal year 2019: -$7.70 million | Fiscal year 2019: -$10.91 million | Fiscal year 2019: -$12.79 million | Fiscal year 2019: -$8.82 million | Fiscal year 2018: -$8.66 million | Fiscal year 2018: -$9.12 million | Fiscal year 2018: -$8.57 million | Fiscal year 2018: -$8.55 million | Fiscal year 2017: -$7.80 million | Fiscal year 2017: -$5.25 million | Fiscal year 2017: -$3.93 million | Fiscal year 2017: -$1.37 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: